发明授权
US08461318B2 Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder thereapeutics
有权
适应组织因子途径抑制剂及其作为出血性疾病的治疗药物
- 专利标题： Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder thereapeutics
- 专利标题（中）： 适应组织因子途径抑制剂及其作为出血性疾病的治疗药物
-
申请号： US13288634申请日： 2011-11-03
-
公开(公告)号： US08461318B2公开(公告)日： 2013-06-11
- 发明人: Robert Schaub , Kathleen McGinness , Jennifer Nelson , Ryan Genga , Emily Waters , Jeffrey Kurz , John Diener
- 申请人： Robert Schaub , Kathleen McGinness , Jennifer Nelson , Ryan Genga , Emily Waters , Jeffrey Kurz , John Diener
- 申请人地址： US IL Deerfield CH Glattpark (Opfikon)
- 专利权人： Baxter International Inc.,Baxter Healthcare S.A.
- 当前专利权人： Baxter International Inc.,Baxter Healthcare S.A.
- 当前专利权人地址： US IL Deerfield CH Glattpark (Opfikon)
- 代理机构： Morgan, Lewis & Bockius LLP
- 主分类号： C07H21/02
- IPC分类号： C07H21/02 ; C07H21/04 ; A61K38/36
摘要：
The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.
公开/授权文献
信息查询
